Fed. Circ. Says Sandoz Didn't Infringe Cancer Drug Patent
Novartis AG subsidiary Sandoz Inc. didn't infringe Spectrum Pharmaceuticals Inc. and the University of Strathclyde's patent for the cancer drug Fusilev when filing an application to make a generic version of...To view the full article, register now.
Already a subscriber? Click here to view full article